Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Umbilical cord blood transplant from unrelated HLA-mismatched donors in children with high risk leukemia.
Arcese W, Guglielmi C, Iori AP, Screnci M, Carmini D, Testi AM, Moleti ML, Mengarelli A, Del Giudice I, Cimino G, Elia L, Rapanotti MC, Perrone P, Laurenti L, Gentile G, Boecklin F, Romano A, De Felice L, Mandelli F. Arcese W, et al. Among authors: del giudice i. Bone Marrow Transplant. 1999 Mar;23(6):549-54. doi: 10.1038/sj.bmt.1701615. Bone Marrow Transplant. 1999. PMID: 10217184
Additional lesions identified by genomic microarrays are associated with an inferior outcome in low-risk chronic lymphocytic leukaemia patients.
Rigolin GM, Traversa A, Caputo V, Del Giudice I, Bardi A, Saccenti E, Raponi S, Ilari C, Cafforio L, Giovannetti A, Pizzuti A, Guarini A, Foà R, Cuneo A. Rigolin GM, et al. Among authors: del giudice i. Br J Haematol. 2023 Sep;202(5):953-959. doi: 10.1111/bjh.18946. Epub 2023 Jun 26. Br J Haematol. 2023. PMID: 37357817
XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling.
Moia R, Terzi di Bergamo L, Talotta D, Bomben R, Forestieri G, Spina V, Bruscaggin A, Cosentino C, Almasri M, Dondolin R, Bittolo T, Zucchetto A, Baldoni S, Del Giudice I, Mauro FR, Maffei R, Chiarenza A, Tafuri A, Laureana R, Del Principe MI, Zaja F, D'Arena G, Olivieri J, Rasi S, Mahmoud A, Al Essa W, Awikeh B, Kogila S, Bellia M, Mouhssine S, Sportoletti P, Marasca R, Scarfò L, Ghia P, Gattei V, Foà R, Rossi D, Gaidano G. Moia R, et al. Among authors: del giudice i. Br J Haematol. 2023 Nov;203(3):416-425. doi: 10.1111/bjh.19052. Epub 2023 Aug 14. Br J Haematol. 2023. PMID: 37580908
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature.
Del Giudice I, Cappelli LV, Delgado J, Niemann CU, Andersen MA, Rotbain EHC, Aarup K, Walewska R, Visentin A, Deodato M, Frustaci AM, Cavalloni C, Gentile M, Yassin MA, Lad D, Scarfò L, Flogegard M, Mattsson M, Raponi S, Ilari C, Starza ID, Orlandi EM, Tedeschi A, Trentin L, Semenzato G, Guarini A, Ghia P, Montserrat E, Foà R. Del Giudice I, et al. Br J Haematol. 2023 Apr;201(2):353-356. doi: 10.1111/bjh.18696. Epub 2023 Feb 15. Br J Haematol. 2023. PMID: 36793194 Review. No abstract available.
A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome.
Testi AM, Moleti ML, Giona F, Annino L, Chiaretti S, Del Giudice I, Todisco E, D'Elia G, Ferrari A, Arcese W, Mandelli F. Testi AM, et al. Among authors: del giudice i. Haematologica. 1997 Nov-Dec;82(6):664-7. Haematologica. 1997. PMID: 9499665 Clinical Trial.
A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia: a study of the AIEOP group.
Testi AM, Del Giudice I, Arcese W, Moleti ML, Giona F, Basso G, Biondi A, Conter V, Messina C, Rondelli R, Micozzi A, Micalizzi C, Barisone E, Locatelli F, Dini G, Aricò M, Casale F, Comis M, Ladogana S, Lippi A, Mura R, Pinta MF, Santoro N, Valsecchi MG, Masera G, Mandelli F; AIEOP Cooperative Group. Testi AM, et al. Among authors: del giudice i. Br J Haematol. 2002 Sep;118(3):741-7. doi: 10.1046/j.1365-2141.2002.03706.x. Br J Haematol. 2002. PMID: 12181040 Free article. Clinical Trial.
Long-term follow-up of Philadelphia chromosome-positive (Ph) chronic myeloid leukaemia (CML) in children and adolescents managed at a single institution over a 20-year period.
Giona F, Moleti ML, Del Giudice I, Testi AM, Diverio D, De Cuia MR, Mandelli F, Foa R. Giona F, et al. Among authors: del giudice i. Br J Haematol. 2005 Sep;130(6):970-2. doi: 10.1111/j.1365-2141.2005.05731.x. Br J Haematol. 2005. PMID: 16156873 Free article. No abstract available.
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile.
Mauro FR, Molica S, Laurenti L, Cortelezzi A, Carella AM, Zaja F, Chiarenza A, Angrilli F, Nobile F, Marasca R, Musolino C, Brugiatelli M, Piciocchi A, Vignetti M, Fazi P, Gentile G, De Propris MS, Della Starza I, Marinelli M, Chiaretti S, Del Giudice I, Nanni M, Albano F, Cuneo A, Guarini A, Foà R; Gruppo Italiano Malattie EMatologiche dell’Adulto Working Party for Chronic Lymphoproliferative Disorders. Mauro FR, et al. Among authors: del giudice i. Leuk Res. 2014 Feb;38(2):198-203. doi: 10.1016/j.leukres.2013.11.009. Epub 2013 Nov 19. Leuk Res. 2014. PMID: 24314589 Clinical Trial.
122 results